Drugs / Disitamab Vedotin for Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06389006 | Apr 2024 → Jun 2025 overdue | breast cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-10-15 | RemeGen Co., Ltd. | Regulatory BLA Accepted and Priority Review Granted to Disitamab Vedotin for Its Third Indication of HER2-Positive Advanced Breast Cancer with Liver Metastasis remegen.com ↗ |
| 2023-02-16 | RemeGen Co., Ltd. | Regulatory RemeGen Disitamab Vedotin in Combination with Pyrotinib Maleate Tablets in the Treatment of Non-Small Cell Lung Cancer Approved for Clinical Trials remegen.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Disitamab Vedotin for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06389006 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06389006 ↗ |